Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Venlafaxine, a serotonin and norepinephrine reuptake inhibitor (SNRI), produces significantly higher remission rates in depressed patients than do the selective serotonin reuptake inhibitors (SSRIs). In this analysis of pooled data, we explored the relationship between differences in treatment efficacy, early improvement of symptoms, and severity of baseline anxiety in depressed patients treated with either venlafaxine or fluoxetine. A pooled analysis was performed on data from 1,454 outpatients with major depression from five double-blind, randomized studies comparing the 6-week efficacy of venlafaxine (542 patients) with fluoxetine (555 patients). The Hamilton rating scale for depression (HAM-D) total and item scores were analyzed at different treatment times up to 6 weeks. Venlafaxine and fluoxetine both produced statistically significant higher response and remission rates compared with placebo starting from week 2 for response and weeks 3 to 4 for remission. Venlafaxine was statistically significantly superior to fluoxetine from week 3 until week 6 in respect of response rate, and from week 2 until week 6 for remission rate. After 1 week of treatment, greater improvement in individual symptoms was observed in the depressed mood, suicide, and psychic anxiety items of the HAM-D scale for both venlafaxine- and fluoxetine-treated patients compared with placebo. Improvement in psychic anxiety was statistically significantly greater with venlafaxine than with fluoxetine. The presence of baseline psychic anxiety correlated significantly to treatment outcome when analyzing the remission rates. In depressed patients with moderate anxiety (HAM-D psychic anxiety score < or = 2), venlafaxine statistically significantly increased remission rates compared with placebo from week 4 until week 6, while a significant effect of fluoxetine on remission rates was observed starting at week 6. Remission rates in the severely anxious depressed patients (score > 2) were statistically significantly higher with venlafaxine than placebo starting from week 3 until the end of the study period, but no difference could be observed between fluoxetine and placebo. Baseline severity of psychic anxiety had a significant impact on remission rates after treatment of patients diagnosed with depression. Venlafaxine's superior remission rates in the more severely anxious patients and its ability to improve psychic anxiety as early as week 1 compared with fluoxetine suggest that venlafaxine's early efficacy on anxiety symptoms may be the basis for its superior efficacy in depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey
Wittchen, H.-U. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950050015002 · Cited by 967 · cited 1×
“The incidence of comorbid anxiety and major depression is high in the psychiatric population, and up to 39% of patients diagnosed with current generalized anxiety disorder (GAD) also had major depression [Wittchen et al., 1994].”
BackgroundRoy-Byrne, P. P., Stang, P., Wittchen, H.-U., Ustun, B., Walters, E. E., & Kessler, R. C. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.3.229 · Cited by 446 · cited 2×
“…it is associated with a worse prognosis and poorer outcome [Van Valkenburg et al., 1984; Grunhaus, et al., 1988] and with increased incidences of suicide, social distress, and alcohol and drug abuse [Fawcett and Kravitz, 1983; Fawcett, 1992; Roy-Byrne et al., 2000; Vollrath and Angst, 1989].”
BackgroundMuth, E. A., Haskins, J. T., Moyer, J. A., Husbands, G. E. M., Nielsen, S. T., & Sigg, E. B. (1986) · Biochemical Pharmacology · doi:10.1016/0006-2952(86)90769-0 · Cited by 374 · cited 1×
“…reuptake inhibitors (SNRIs), that increase both serotonin and norepinephrine levels by inhibiting the reuptake of both neurotransmitters [Muth et al., 1986, 1991] and has low affinity with the postsynaptic receptors usually responsible for side effects of first generation…”
BackgroundExactly what does the Hamilton depression rating scale measure?
Gibbons, R. D., Clark, D. C., & Kupfer, D. J. (1993) · Journal of Psychiatric Research · doi:10.1016/0022-3956(93)90037-3 · Cited by 223
Rudolph, R. L., & Feiger, A. D. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00067-1 · Cited by 158 · cited 2×
“…total score, last observation carried forward (LOCF) analysis on the ITT population. bVenlafaxine vs. placebo. cFluoxetine vs. placebo. dVenlafaxine vs. fluoxetine. elsewhere [Silverstone et al., 1998; Clerc et al., 1994; Dierick et al., 1996; Rudolph and Feiger, 1999; Rudolph et al., 1998].”
BackgroundMethodRickels, K., DeMartinis, N., García-España, F., Greenblatt, D. J., Mandos, L. A., & Rynn, M. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.12.1973 · Cited by 110 · cited 6×
“The incidence of comorbid anxiety and major depression is high in the psychiatric population, and up to 39% of patients diagnosed with current generalized anxiety disorder (GAD) also had major depression [Wittchen et al., 1994].”
MethodInfluential
Cited by
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Fava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111868 · Cited by 927
Stahl, S. M., Grady, M. M., Moret, C., & Briley, M. (2005) · CNS Spectrums · doi:10.1017/s1092852900019726 · Cited by 458
Maj, M., Stein, D. J., Parker, G., Zimmerman, M., Fava, G. A., De Hert, M., Demyttenaere, K., McIntyre, R. S., Widiger, T., & Wittchen, H. (2020) · World Psychiatry · doi:10.1002/wps.20771 · Cited by 435
FAVA, M., ALPERT, J. E., CARMIN, C. N., WISNIEWSKI, S. R., TRIVEDI, M. H., BIGGS, M. M., SHORES-WILSON, K., MORGAN, D., SCHWARTZ, T., BALASUBRAMANI, G. K., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291704002612 · Cited by 406
Metadata
- Authors
- Davidson, J. R. T., Meoni, P., Haudiquet, V., Cantillon, M., & Hackett, D.
- Venue
- Depression and Anxiety
- Publisher
- Hindawi Limited
- Published
- 2002
- Volume
- 16
- Issue
- 1
- Pages
- 4-13
- ISSN
- 1091-4269 (ISSN-L)
- 1520-6394
- OpenAlex
- W2125412819
- Cited by
- 131
- References
- 6
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. https://app.cochat.ai/papers/10.1002/da.10045
- The paper
- Davidson, J. R. T., Meoni, P., Haudiquet, V., Cantillon, M., & Hackett, D. (2002). Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depression and Anxiety. https://doi.org/10.1002/da.10045
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.